Report on the Responsible Industrial Development of Precision Medicine
Click here to download the Report on the Responsible Industrial Development of Precision Medicine.
The Report on the Responsible Industrial Development of Precision Medicine provides:
- reflections on field specific challenges;
- suggestions for a flexible and tested RRI approach to be implemented in industrial innovation processes;
- a list of stakeholder-specific concrete actions;
- evidence of potential benefits for companies and other stakeholders involved;
- an overview of the whole process performed during the SMART-map project
The Report on the Responsible Industrial Development of Precision Medicine is the outcome of a two-years-long process which started with two Industrial Dialogues and concluded with a Pilot activity. The process has led to the identification of a long list of benefits deriving from adopting Responsible Research and Innovation (RRI) practices in this industrial context.
The precision medicine Industrial Dialogues consisted of two workshops that took place in Aarhus (Denmark) and Valencia (Spain) during the first quarter of 2017. The Industrial Dialogues brought together actors from industry, civil society and the public sector with the goal to co-design tools that can enable businesses to address questions of social and environmental responsibility they face in their innovation processes.
One of the tools identified through the Industrial Dialogues has been tested during the precision medicine Pilot activity, which represents a valuable and inspiring example of successful implementation of RRI in an industrial context.
During the Pilot, Imegen, a Spanish SME specialized in genetic studies and partner of SMART-map, has tested the introduction of an end-user advisory panel, involving patients and doctors, with the aim of experimenting a new approach and achieving concrete impact on one of their products: IMExoma, a specific DNA sequencing technique.
When discussing about the company’s involvement in the Pilot, M.Carmen Alvarez, Strategic Assistant to CEO at Imegen, explains that “Participating in the SMART-map pilot has provided us with a new vision of the concrete needs which surround our products. It has also contributed to portray to society the image of Imegen as a company which is aware of the social and ethical problems that genetic testing entails. We believe that in addition to the short-term concrete impact, measurable in terms of actions which we are already implementing, adopting RRI approaches and tools in the future and implementing them in our daily activity will allow us in the long term to have a better connection to real societal needs in the area of precision medicine.”
According to Francesco Lescai, SMART-map coordinator and Associate Professor in Genomics and Bioinformatics at Aarhus University, “The pilot has provided an opportunity for the company to build better strategies and anticipate trends – form a technology point of view but also in terms of market trends and needs of the patients. Therefore this kind of experience can provide a long-term benefit to the company in building their business and creating new business models.”